Terms: = Lymphoma AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
38 results:
1. treatment outcomes and prognostic factors of patients with lymphoblastic lymphoma in East Asia.
Kim J; Byun JM; Hong J; Koh Y; Shin DY; Kim TM; Yoon SS; Park H; Kim I
Medicine (Baltimore); 2024 Feb; 103(7):e37100. PubMed ID: 38363899
[TBL] [Abstract] [Full Text] [Related]
2. Differentiation of cancer of unknown primary and lymphoma in head and neck metastatic poorly differentiated cancer using 18 F-FDG PET/CT tumor metabolic heterogeneity index.
Xu M; Gu B; Zhang J; Xu X; Qiao Y; Hu S; Song S
Nucl Med Commun; 2024 Feb; 45(2):148-154. PubMed ID: 38095143
[TBL] [Abstract] [Full Text] [Related]
3. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
Gordon MJ; Duan Z; Zhao H; Nastoupil L; Ng S; Danilov AV; Iyer S; Giordano SH
Leuk Lymphoma; 2023 Dec; 64(14):2258-2268. PubMed ID: 37706491
[TBL] [Abstract] [Full Text] [Related]
4. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract] [Full Text] [Related]
5. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
6. Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.
Kriachok I; Stepanishyna Y; Skrypets T; Shokun N; Martynchyk A; Tytorenko I; Aleksik O; Krotevych M; Manni M; Federico M
Hematol Oncol; 2023 Feb; 41(1):196-200. PubMed ID: 35932211
[TBL] [Abstract] [Full Text] [Related]
7. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract] [Full Text] [Related]
8. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract] [Full Text] [Related]
9. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
[TBL] [Abstract] [Full Text] [Related]
10. Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study.
Notsumata K; Nomura Y; Tanaka A; Nomura Y; Ueda T; Sanada T; Watanabe H; Toya D
Intern Med; 2020; 59(20):2457-2464. PubMed ID: 33055468
[TBL] [Abstract] [Full Text] [Related]
11. Secondhand smoke: A new and modifiable prognostic factor in childhood acute lymphoblastic leukemias.
Cárceles-Álvarez A; Ortega-García JA; López-Hernández FA; Fuster-Soler JL; Ramis R; Kloosterman N; Castillo L; Sánchez-Solís M; Claudio L; Ferris-Tortajada J
Environ Res; 2019 Nov; 178():108689. PubMed ID: 31479979
[TBL] [Abstract] [Full Text] [Related]
12. Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis.
Okuchi S; Rojas-Garcia A; Ulyte A; Lopez I; Ušinskienė J; Lewis M; Hassanein SM; Sanverdi E; Golay X; Thust S; Panovska-Griffiths J; Bisdas S
Cancer Med; 2019 Sep; 8(12):5564-5573. PubMed ID: 31389669
[TBL] [Abstract] [Full Text] [Related]
13. Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.
Takada K; Shimokawa M; Akamine T; Ono Y; Haro A; Osoegawa A; Tagawa T; Mori M
Anticancer Res; 2019 Apr; 39(4):1987-1996. PubMed ID: 30952742
[TBL] [Abstract] [Full Text] [Related]
14. Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin lymphoma.
Jhawar SR; Rivera-Núñez Z; Drachtman R; Cole PD; Hoppe BS; Parikh RR
JAMA Oncol; 2019 May; 5(5):689-695. PubMed ID: 30605220
[TBL] [Abstract] [Full Text] [Related]
15. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
[No Abstract] [Full Text] [Related]
16. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
[TBL] [Abstract] [Full Text] [Related]
17. [Surgical treatment and prognostic analysis for 57 patients with gastrointestinal lymphoma].
Peng J; Xiao B; Zhao Y; Li C; Zhang R; Chen G; Li L; Lu Z; Ding P; Wan D; Pan Z; Wu X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1040-1044. PubMed ID: 28900997
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Simonitsch-Klupp I; Kornauth C; Dolak W; Lukas J; Mayerhoefer ME; Raderer M
Hematol Oncol; 2018 Feb; 36(1):62-67. PubMed ID: 28833354
[TBL] [Abstract] [Full Text] [Related]
19. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
Pemmaraju N; Kantarjian H; Jorgensen JL; Jabbour E; Jain N; Thomas D; O'Brien S; Wang X; Huang X; Wang SA; Konopleva M; Konoplev S; Kadia T; Garris R; Pierce S; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2017 Mar; 92(3):279-285. PubMed ID: 28052371
[TBL] [Abstract] [Full Text] [Related]
20. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract] [Full Text] [Related]
[Next]
